THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, July 21, 2021
MediPharm Labs is happy to announce that Health Canada has granted a Drug Establishment License (the DEL) under the Food and Drugs Act and Regulations.
FREMONT, CA: MediPharm Labs Corp., a pharmaceutical firm specializing in the research-driven development and manufacturing of cannabis API and finished products, is delighted to announce that Health Canada has granted the company a Drug Establishment License (the DEL) under the Food and Drugs Act and Regulations. The DEL is used to certify that Good Manufacturing Practice (GMP) standards are being followed.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
In North America, the DEL is the first innovative cannabis manufacturing license. MediPharm Labs' current Australian TGA GMP certification is complemented by a Canadian GMP DEL. The license allows the production, testing, and marketing of cannabis-based Active Pharmaceutical Ingredients (API) and pharmaceutical drug products. This comprises cannabis-containing medications with innovative or generic pharmaceutical drug product marketing authorizations.
The DEL enables MediPharm Labs to take advantage of MRAs established between Canada and other global regulatory authorities, such as the European Economic Area, which includes all EU member states, and the three countries of the European Free Trade Association, Australia, the United Kingdom, and Switzerland. This sets MediPharm Labs apart from other cannabis manufacturers in Canada.
The Health Canada DEL is also recognized in more than 50 countries, including the United States and the majority of the European Union, as a member of the International Pharmaceutical Inspection Co-operation Scheme. If the US or other worldwide pharmaceutical customer submits a registration application for a pharmaceutical drug product incorporating MediPharm Labs API, MediPharm Labs would be qualified for a foreign inspection by the US Food and Drug Administration (FDA) with DEL. In 2020, the FDA approved 64 percent of pharmaceuticals exported from Canadian Drug Establishment Licence holders to the United States. In 2021, MediPharm Labs will employ the DEL in conjunction with its Australian facility TGA GMP to optimize the supply chain through MRAs for export to more than five nations.
"MediPharm Labs has achieved a great milestone with the issuance of our Drug Establishment Licence. This truly makes us a full-service pharmaceutical company that can support global pharmas entry into the drugs containing cannabis space," explained Keith Strachan, President, and Interim CEO, MediPharm Labs. "This adds to our growing portfolio of advanced regulatory licences globally. MediPharm Labs now becomes one of a small number of companies who can take cannabis plant material and produce an API or a pharmaceutical drug product that could have marketing authorization by regulatory bodies such as the European Medicines Agency and FDA."
More in News